To test the ability of the combined therapy in treating cancerous tumors, senior author Wafik S. El-Deiry, MD, PhD, and colleagues administered TRAIL, a tumor necrosis factor, and sorafenib, an inhibitor currently used to treat renal cancer, to mice with colon carcinomas. The sorafenib and TRAIL therapy reduced the size of tumors in mice with few side effects, demonstrating the potential effectiveness of the combined treatment on human colon cancers.
"Cancer cells will do whatever it takes to survive in harsh environments," explains El-Deiry, Professor of Medicine, Genetics, and Pharmacology. To kill hearty cancer cells, El-Deiry and other scientists are working on ways to alter them so they become more susceptible to cell death.
In ongoing clinical trials, doctors are giving cancer patients extra doses of TRAIL (TNF-a-related apoptosis-inducing ligand), a molecule naturally produced by the body's immune system that promotes cell death, to help kill off cancer cells. While TRAIL-based therapy is promising, over 50 percent of all cancer cells show resistance to TRAIL. To create a more potent form of targeted cancer therapy, El-Deiry's research team began searching for ways to reverse TRAIL resistance in cancer cells.
Recently, El-Deiry's research group found that TRAIL-resistant cells avoid death by producing 'survival' proteins called cIAP2 and Mcl-1. The oncogene c-Myc in part hampers a cancer cell's survival strategy by blocking the function of an intermediate protein that oversees cIAP2 and Mcl-1 production. Without these survival proteins, cancer cells are unable to resist the death initiated by TRAIL.
In search of drugs that perform a similar cancer-cell death function to c-Myc, El-Deiry's lab turned to sorafenib, which is also being considered for the treatment of a variety of cancers. Like c-Myc, the researchers found that sorafenib blocked the intermediate and survival proteins when combined with TRAIL, causing TRAIL-resistant colon and lung cancer cell lines to die.
"Our findings are exciting because TRAIL in combination with sorafenib appears to be much less toxic than current chemotherapy drugs," explains El-Deiry. "Plus, sorafenib is already available in a pill form."¨
While enthusiastic about his recent findings, El-Deiry notes sorafenib may be working to increase cell sensitivity to TRAIL through more biochemical pathways than the intermediate alone.
"The ability of sorafenib to work through multiple pathways may be beneficial to cancer treatments because cancer may be altering multiple targets," says El-Deiry.
In the future, El-Deiry plans to explore additional pathways sorafenib may be working through to increase TRAIL sensitivity and to compare the effectiveness of other drugs.
"In addition to proposing a combination therapy that's rational, non-toxic, and effective in preclinical trials, our findings open up new avenues of molecular exploration for designing targeted anti-cancer therapies," said El-Deiry.
Karen Kreeger | EurekAlert!
Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Power and Electrical Engineering
06.12.2016 | Earth Sciences
06.12.2016 | Physics and Astronomy